NaturoMed Therapeutics, the parent company of Stay Wyld Organics, is a vertically integrated functional and medicinal mushroom company. NaturoMed Therapeutics is currently producing bulk functional mushroom powders at its state of the art facility in BC, Canada and selling functional mushroom products to the retail market throughout North America. The company is committed to improving global mental and physical health through the production and distribution of high-quality Canadian grown organic mushroom products. NaturoMed is excited to announce that construction is well underway for its Health Canada Controlled Substances Dealer’s License to produce Psilocybin. Estimated completion is Q4, 2022. NaturoMed plans to produce Psilocybin once it receives the license. NaturoMed’s lead scientist is currently working on new extraction processes to create medicinal IP.
Similar Posts
CEO of Canadian Stock Exchange on Psychedelic Investments
Listening to Richard Carleton – the CEO of the Canadian…
Awakn Life Sciences CEO Details ‘Groundbreaking’ MDMA Discovery in Quest to Treat Addiction
Anthony Tennyson tells the Psychedelic Spotlight Podcast that his company has “discovered receptor sites that MDMA interacts with that we believe nobody else in the world knows about.”
New Synthetic Ibogaine Treats Addiction With Fewer Side Effects
A new version of synthetic ibogaine can treat opioid addiction but with a decreased risk of cardiac arrhythmias.
Field Trip Is the Latest Psychedelic Therapy Company to Go Public
Another psychedelic therapy-based company has gone public. Toronto-based Field Trip…
Psilocybin Provides Long-Term Relief of Cancer-Related Anxiety, Depression: Study
A follow-up study has found long-term relief from anxiety and depression related to cancer diagnoses with use of psilocybin treatment.
This Week in Psychedelic Stocks [UPDATES ON MINDMED (MMED/MMEDF) CMPS, NUMI & ATAI, CYBIN]
In today’s episode of “This Week in Psychedelic Stocks”, we’ll see some news on MindMed (MMED / MMEDF/MMQ), Compass Pathways (CMPS), Atai Life Sciences, Numinus Wellness (NUMI), Cybin.
We will cover the latest developments in the field writ large.
This means we will cover any stories that affect the all the companies in this field, as well as company specific developments.
Timestamps:
0:00 – Intro
0:32 – Norway Decriminalization Bill
1:59 – Psychedelic Market Stats
3:21 – Magic Mushrooms to Treat Obesity
5:40 – Ketamine to Treat Suicidal Thoughts?
7:09 -The Acid King?
8:58 – MindMed (MMED/MMEDF/MMQ) Updates
10:04 – Compass Pathways (CMPS) Updates
11:44 – Atai Life Sciences Updates
14:02 – Numinus (NUMI) Updates
15:13 – CYBIN Updates
So this is it for This Week in Psychedelic Stocks fellow psychedelic investors!
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedStock #PsychedelicStocks